Thermo Fisher Scientific Inc.

LSE:0R0H Stock Report

Market Cap: US$200.4b

Thermo Fisher Scientific Valuation

Is 0R0H undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R0H when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0R0H ($523.46) is trading below our estimate of fair value ($824.4)

Significantly Below Fair Value: 0R0H is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R0H?

Key metric: As 0R0H is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0R0H. This is calculated by dividing 0R0H's market cap by their current earnings.
What is 0R0H's PE Ratio?
PE Ratio32.7x
EarningsUS$6.14b
Market CapUS$200.45b

Price to Earnings Ratio vs Peers

How does 0R0H's PE Ratio compare to its peers?

The above table shows the PE ratio for 0R0H vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.2x
AZN AstraZeneca
30.8x18.2%UK£159.0b
GSK GSK
21.5x23.2%UK£53.9b
ERGO Ergomed
46.7x14.2%UK£701.1m
DHR Danaher
42x13.4%US$165.1b
0R0H Thermo Fisher Scientific
32.7x11.5%US$200.4b

Price-To-Earnings vs Peers: 0R0H is expensive based on its Price-To-Earnings Ratio (32.7x) compared to the peer average (31.4x).

Price to Earnings Ratio vs Industry

How does 0R0H's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0R0H 32.7xIndustry Avg. 37.4xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0R0H is good value based on its Price-To-Earnings Ratio (32.7x) compared to the European Life Sciences industry average (37.4x).

Price to Earnings Ratio vs Fair Ratio

What is 0R0H's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R0H PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.7x
Fair PE Ratio36.3x

Price-To-Earnings vs Fair Ratio: 0R0H is good value based on its Price-To-Earnings Ratio (32.7x) compared to the estimated Fair Price-To-Earnings Ratio (36.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R0H forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$523.46
US$651.40
+24.4%
5.8%US$767.00US$585.20n/a28
Dec ’25US$529.63
US$653.94
+23.5%
5.8%US$767.00US$585.20n/a28
Nov ’25US$558.73
US$656.23
+17.5%
5.5%US$767.00US$600.00n/a27
Oct ’25US$612.78
US$652.08
+6.4%
5.9%US$767.00US$565.00n/a26
Sep ’25US$607.82
US$632.44
+4.1%
4.6%US$690.00US$565.00n/a25
Aug ’25US$618.51
US$631.92
+2.2%
4.4%US$677.00US$565.00n/a25
Jul ’25US$541.14
US$628.80
+16.2%
4.5%US$677.00US$553.00n/a25
Jun ’25US$563.05
US$627.47
+11.4%
4.5%US$677.00US$553.00n/a25
May ’25US$573.73
US$624.45
+8.8%
4.8%US$677.00US$553.00n/a26
Apr ’25US$580.91
US$599.75
+3.2%
5.5%US$677.00US$520.00n/a26
Mar ’25US$576.17
US$598.94
+4.0%
5.6%US$677.00US$520.00n/a25
Feb ’25US$548.62
US$585.04
+6.6%
5.8%US$650.00US$520.00n/a23
Jan ’25US$530.23
US$547.44
+3.2%
9.4%US$640.00US$435.00n/a25
Dec ’24US$495.90
US$531.22
+7.1%
8.8%US$635.00US$435.00US$529.6323
Nov ’24US$440.76
US$534.70
+21.3%
9.2%US$635.00US$435.00US$558.7323
Oct ’24US$508.12
US$622.00
+22.4%
6.3%US$693.00US$520.00US$612.7824
Sep ’24US$558.00
US$626.67
+12.3%
6.2%US$693.00US$520.00US$607.8224
Aug ’24US$545.93
US$628.12
+15.1%
6.2%US$698.00US$520.00US$618.5125
Jul ’24US$522.33
US$628.29
+20.3%
7.2%US$700.00US$505.00US$541.1424
Jun ’24US$519.86
US$628.87
+21.0%
7.2%US$700.00US$505.00US$563.0523
May ’24US$556.78
US$636.91
+14.4%
7.2%US$710.00US$505.00US$573.7322
Apr ’24US$574.25
US$648.91
+13.0%
7.1%US$711.00US$505.00US$580.9122
Mar ’24US$541.20
US$648.91
+19.9%
7.1%US$711.00US$505.00US$576.1722
Feb ’24US$584.99
US$634.46
+8.5%
8.5%US$711.00US$505.00US$548.6219
Jan ’24US$550.12
US$617.94
+12.3%
8.2%US$715.00US$525.00US$530.2322
Dec ’23US$564.11
US$615.69
+9.1%
8.5%US$715.00US$525.00US$495.9020

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 13:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/28
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Thermo Fisher Scientific Inc. is covered by 55 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kadambari DaptardarAccountability Research Corporation
David ToungArgus Research Company
Catherine Ramsey SchulteBaird